H Findeis1, V Ludwig1, P Mikolas1, J Graff1, M Bauer1, Philipp Ritter2. 1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus An der Technischen Universität Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. 2. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus An der Technischen Universität Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. philipp.ritter@uniklinikum-dresden.de.
Abstract
BACKGROUND: Although multiple studies and meta-analyses have documented the rapid antidepressive efficacy of ketamine, there are numerous questions regarding the practical use in the clinical routine that are still unanswered. OBJECTIVE: Based on personal clinical experience, by comparison and supplementation of the current data situation, answers are given to questions regarding the practical use of ketamine for depression that have not yet been satisfactorily clarified. MATERIAL AND METHODS: The clinical experiences with antidepressive treatment using ketamine over more than 5 years were evaluated with respect to the questions at hand. This was followed by a qualitative comparison of these results with those of a narrative literature search. RESULTS: A total of 72 patients (unipolar depression n = 53, bipolar depression n = 16, schizoaffective depression n = 3) were included in the analysis of this cohort. A statistically significant reduction of depressive symptoms and suicidal ideation after S-ketamine treatment was found. Of the patients 61% suffered from at least one secondary diagnosis. A dose of 0.5 mg/kg body weight of S‑ketamine at a frequency of three times per week was shown to be effective. The treatment appears to be safe with respect to urotoxic side effects, combination treatment with tranylcypromine and in comorbid posttraumatic stress disorder. CONCLUSION: Ketamine appears to be a safe and effective option for the treatment of unipolar and bipolar depression.
BACKGROUND: Although multiple studies and meta-analyses have documented the rapid antidepressive efficacy of ketamine, there are numerous questions regarding the practical use in the clinical routine that are still unanswered. OBJECTIVE: Based on personal clinical experience, by comparison and supplementation of the current data situation, answers are given to questions regarding the practical use of ketamine for depression that have not yet been satisfactorily clarified. MATERIAL AND METHODS: The clinical experiences with antidepressive treatment using ketamine over more than 5 years were evaluated with respect to the questions at hand. This was followed by a qualitative comparison of these results with those of a narrative literature search. RESULTS: A total of 72 patients (unipolar depression n = 53, bipolar depression n = 16, schizoaffective depression n = 3) were included in the analysis of this cohort. A statistically significant reduction of depressive symptoms and suicidal ideation after S-ketamine treatment was found. Of the patients 61% suffered from at least one secondary diagnosis. A dose of 0.5 mg/kg body weight of S‑ketamine at a frequency of three times per week was shown to be effective. The treatment appears to be safe with respect to urotoxic side effects, combination treatment with tranylcypromine and in comorbid posttraumatic stress disorder. CONCLUSION: Ketamine appears to be a safe and effective option for the treatment of unipolar and bipolar depression.
Authors: R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal Journal: Biol Psychiatry Date: 2000-02-15 Impact factor: 13.382
Authors: Gustavo C Leal; Igor D Bandeira; Fernanda S Correia-Melo; Manuela Telles; Rodrigo P Mello; Flavia Vieira; Cassio S Lima; Ana Paula Jesus-Nunes; Lívia N F Guerreiro-Costa; Roberta F Marback; Ana Teresa Caliman-Fontes; Breno L S Marques; Marília L O Bezerra; Alberto L Dias-Neto; Samantha S Silva; Aline S Sampaio; Gerard Sanacora; Gustavo Turecki; Colleen Loo; Acioly L T Lacerda; Lucas C Quarantini Journal: Eur Arch Psychiatry Clin Neurosci Date: 2020-02-20 Impact factor: 5.270
Authors: Ella J Daly; Madhukar H Trivedi; Adam Janik; Honglan Li; Yun Zhang; Xiang Li; Rosanne Lane; Pilar Lim; Anna R Duca; David Hough; Michael E Thase; John Zajecka; Andrew Winokur; Ilona Divacka; Andrea Fagiolini; Wieslaw J Cubala; István Bitter; Pierre Blier; Richard C Shelton; Patricio Molero; Husseini Manji; Wayne C Drevets; Jaskaran B Singh Journal: JAMA Psychiatry Date: 2019-09-01 Impact factor: 21.596
Authors: Adriana Feder; Sara Costi; Sarah B Rutter; Abigail B Collins; Usha Govindarajulu; Manish K Jha; Sarah R Horn; Marin Kautz; Morgan Corniquel; Katherine A Collins; Laura Bevilacqua; Andrew M Glasgow; Jess Brallier; Robert H Pietrzak; James W Murrough; Dennis S Charney Journal: Am J Psychiatry Date: 2021-01-05 Impact factor: 18.112
Authors: Adriana Feder; Michael K Parides; James W Murrough; Andrew M Perez; Julia E Morgan; Shireen Saxena; Katherine Kirkwood; Marije Aan Het Rot; Kyle A B Lapidus; Le-Ben Wan; Dan Iosifescu; Dennis S Charney Journal: JAMA Psychiatry Date: 2014-06 Impact factor: 21.596
Authors: Naji C Salloum; Maurizio Fava; Rebecca S Hock; Marlene P Freeman; Martina Flynn; Bettina Hoeppner; Cristina Cusin; Dan V Iosifescu; Madhukar H Trivedi; Gerard Sanacora; Sanjay J Mathew; Charles Debattista; Dawn F Ionescu; George I Papakostas Journal: J Affect Disord Date: 2019-09-03 Impact factor: 4.839
Authors: Jordi Bonaventura; Sherry Lam; Meghan Carlton; Matthew A Boehm; Juan L Gomez; Oscar Solís; Marta Sánchez-Soto; Patrick J Morris; Ida Fredriksson; Craig J Thomas; David R Sibley; Yavin Shaham; Carlos A Zarate; Michael Michaelides Journal: Mol Psychiatry Date: 2021-04-15 Impact factor: 13.437